載入...
The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice
A common therapeutic strategy to combat human cancer is the use of combinations of drugs, each targeting different cellular processes or vulnerabilities. Recent studies suggest that addition of an MCL-1 inhibitor to such anticancer drug treatments could be an attractive therapeutic strategy. Thus, i...
Na minha lista:
| 發表在: | Cell Death Differ |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5686343/ https://ncbi.nlm.nih.gov/pubmed/28800129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2017.125 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|